期刊
ONCOGENE
卷 35, 期 3, 页码 279-289出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2015.92
关键词
-
资金
- Cancer Research UK
- Leukemia Lymphoma Research
- Kay Kendal Leukemia Fund
- Leukemia lymphoma Society of America
- Wellcome Trust
- Medical Research Council
- NIHR Cambridge Biomedical Research Centre grant
- BBSRC [BB/I00050X/1] Funding Source: UKRI
- MRC [MR/M010392/1] Funding Source: UKRI
- Academy of Medical Sciences (AMS) [AMS-SGCL10-Gallipoli] Funding Source: researchfish
- Biotechnology and Biological Sciences Research Council [BB/I00050X/1] Funding Source: researchfish
- Cancer Research UK [12765] Funding Source: researchfish
- Medical Research Council [MC_PC_12009, MR/M010392/1] Funding Source: researchfish
- Worldwide Cancer Research [14-1069] Funding Source: researchfish
Growing evidence links abnormal epigenetic control to the development of hematological malignancies. Accordingly, inhibition of epigenetic regulators is emerging as a promising therapeutic strategy. The acetylation status of lysine residues in histone tails is one of a number of epigenetic post-translational modifications that alter DNA-templated processes, such as transcription, to facilitate malignant transformation. Although histone deacetylases are already being clinically targeted, the role of histone lysine acetyltransferases (KAT) in malignancy is less well characterized. We chose to study this question in the context of acute myeloid leukemia (AML), where, using in vitro and in vivo genetic ablation and knockdown experiments in murine models, we demonstrate a role for the epigenetic regulators CBP and p300 in the induction and maintenance of AML. Furthermore, using selective small molecule inhibitors of their lysine acetyltransferase activity, we validate CBP/p300 as therapeutic targets in vitro across a wide range of human AML subtypes. We proceed to show that growth retardation occurs through the induction of transcriptional changes that induce apoptosis and cell-cycle arrest in leukemia cells and finally demonstrate the efficacy of the KAT inhibitors in decreasing clonogenic growth of primary AML patient samples. Taken together, these data suggest that CBP/p300 are promising therapeutic targets across multiple subtypes in AML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据